Based on the structural characteristics of RARs, our previous study has developed a targeted RA analogue, WYC‐209, which effectively inhibits the growth of TRCs from various cancers (including melanoma, breast cancer [BC], ovarian cancer and lung cancer) in vitro. This evidence concerns the gene RARS1 and breast cancer.